The authors' response

• Type of Material: Article
• Authors: Ofer Sadan, Emory University; Owen Samuels, Emory University
• Language: English
• Date: 2020-09-26
• Publisher: BMC
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2020
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1186/s40560-020-00493-w
• Title of Journal or Parent Work: JOURNAL OF INTENSIVE CARE
• Volume: 8
• Issue: 1
• Start Page: 74
• End Page: 74
• Grant/Funding Information: The study is funded in part by PHS grant UL1TR000454 from the Clinical and Translational Science Award program, National Institutes of Health, and the National Center for Advancing Translational Sciences.
• Keywords: Neurocritical care; Science & Technology; Acute kidney injury; General & Internal Medicine; Cerebral edema; Subarachnoid hemorrhage; Hyperchloremia; Critical Care Medicine; Hyperosmolar therapy; Life Sciences & Biomedicine
• Research Categories: Biology, Neuroscience; Health Sciences, Medicine and Surgery; Health Sciences, Health Care Management

Abstract

In response to comments raised, we acknowledge the shortcomings of our study. It is a small study. However, it is a pilot study, which is not meant to create generalizable data, rather to explore new potential directions. To this end, our conclusions were clearly supported by the results. We demonstrated that administration of 16.4% NaCl/Na-acetate solution was feasible, safe, and was associated with lower rates of AKI. We share the call that large RCTs are required to follow this pilot study and hope that our data will stimulate the ongoing discussion regarding the role of chloride in AKI mechanism.